Khorana risk score

Estimate risk of chemotherapy-associated thrombosis

Questions

1.Site of Cancer?
2.Pre-Chemotherapy Platelet Count ≥350 x 10⁹/L
3.Hemoglobin Level <100 g/L or Red Cell Growth Factor Use
4.Pre-Chemotherapy Leukocyte Count >11 X 10⁹
5.BMI ≥35 kg/m²

About

This risk model for chemotherapy-associated thrombosis was developed and validated using an observational cohort of cancer patients initiating chemotherapy within the United States. Inclusion criteria were patients starting a new chemotherapy regimen, and those who were expected to complete at least 4 cycles. Only venous thromboembolism events were included, and were diagnosed by the treating clinician.

Using baseline clinical and biochemical characteristics in patients starting chemotherapy, a risk score for chemotherapy-associated VTE events classifies patients into low, intermediate, and high risk groups.

Previous thromboprophylaxis trials in cancer patients receiving chemotherapy have not demonstrated a significant benefit. Identifying cancer patients at high risk of VTE may help guide clinican decision-making. Prospective trials evaluating the clinical applicability of this score, and its role in patient selection for thromboprophylaxis have not yet been conducted.

References

Khorana AA, Kuderer NM, Culakova E, Lyman GH, Francis CW.

Development and validation of a predictive model for chemotherapy-associated thrombosis.

Blood 2008 May 15, 111 (10): 4902-7

The Khorana risk score calculator is created by QxMD.

Created by on 28/08/2017

By using this site you acknowledge that you have read, understand, and agree to be bound by our terms of use and privacy policy. All content and tools are for educational use only, are not meant to be a substitute for professional advice and should not be used for medical diagnosis and/or medical treatment.

1. Site of Cancer?

0/5 completed